CDRE Cadre Holdings, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1860543 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.3%
TTM net income YoY-9.4%
TTM EPS YoY-18.0%
Revenue 3-yr CAGR15.0%
Net income 3-yr CAGR4.9%
Margins
Gross margin42.0%
Operating margin10.7%
Net margin5.6%
FCF margin10.4%
EBITDA margin13.9%
Returns
ROE11.6%
ROA4.8%
ROIC (approx.)9.0%
Asset turnover0.85x
Leverage & solvency
Liabilities / assets60.2%
Debt / equity1.01x
Current ratio2.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.16x
Accruals ratio-5.6%
Payout ratio40.6%
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $610.31M | $567.56M |
| Cost of revenue | $350.68M | $334.08M |
| Gross profit | $259.63M | $233.48M |
| R&D expense | $11.40M | $8.38M |
| SG&A expense | $183.13M | $158.32M |
| Operating income | $67.35M | $66.76M |
| Interest expense | — | $7.82M |
| Pretax income | $62.33M | $54.22M |
| Income tax | $18.19M | $18.09M |
| Net income | $44.14M | $36.13M |
| EBITDA | $85.98M | $83.18M |
| EPS (basic) | 1.08 | 0.90 |
| EPS (diluted) | 1.02 | 0.90 |
| Dividends declared per share | 0.10 | 0.09 |
| Weighted avg. shares (diluted) | 43.43M | 40.33M |
| Banking | ||
| Deposits | $32.46M | $10.00M |
| Balance sheet | ||
| Cash & equivalents | $122.90M | $124.93M |
| Receivables | $110.61M | $93.52M |
| Inventory | $100.26M | $82.35M |
| Current assets | $365.87M | $327.57M |
| PP&E, net | $78.82M | $45.24M |
| Goodwill | $181.41M | $148.16M |
| Intangibles | $114.98M | $107.54M |
| Total assets | $770.03M | $652.71M |
| Current liabilities | $104.50M | $94.12M |
| Short-term debt | $16.27M | $11.38M |
| Long-term debt | $290.99M | $211.83M |
| Total debt | $307.25M | $223.21M |
| Total liabilities | $452.23M | $341.20M |
| Shareholders' equity | $317.80M | $311.51M |
| Net debt | $184.35M | $98.27M |
| Shares outstanding | 42.16M | 40.61M |
| Cash flow statement | ||
| Operating cash flow | $63.70M | $31.78M |
| Capital expenditure | $6.86M | $5.67M |
| Free cash flow | $56.85M | $26.11M |
| Investing cash flow | -$96.37M | -$147.43M |
| Financing cash flow | $31.59M | $152.67M |
| Depreciation & amortization | $18.63M | $16.42M |
| Stock-based compensation | $12.24M | $8.37M |
| Dividends paid | $15.45M | $13.95M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.